These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 31244095)

  • 1. Activation and Inactivation of the FLT3 Kinase: Pathway Intermediates and the Free Energy of Transition.
    Todde G; Friedman R
    J Phys Chem B; 2019 Jul; 123(26):5385-5394. PubMed ID: 31244095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib.
    Friedman R
    Proteins; 2017 Nov; 85(11):2143-2152. PubMed ID: 28799176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insight into the inhibitor discrimination by FLT3 F691L.
    Verma S; Singh A; Kumari A; Pandey B; Jamal S; Goyal S; Sinha S; Grover A
    Chem Biol Drug Des; 2018 May; 91(5):1056-1064. PubMed ID: 29336115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.
    Ke YY; Singh VK; Coumar MS; Hsu YC; Wang WC; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Shih C; Hsieh HP
    Sci Rep; 2015 Jun; 5():11702. PubMed ID: 26118648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine Kinase Activation and Conformational Flexibility: Lessons from Src-Family Tyrosine Kinases.
    Meng Y; Pond MP; Roux B
    Acc Chem Res; 2017 May; 50(5):1193-1201. PubMed ID: 28426203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational modifications induced by internal tandem duplications on the FLT3 kinase and juxtamembrane domains.
    Todde G; Friedman R
    Phys Chem Chem Phys; 2019 Aug; 21(34):18467-18476. PubMed ID: 31342980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Activation of c-Src Tyrosine Kinase: Conformational Transition Pathway and Free Energy Landscape.
    Fajer M; Meng Y; Roux B
    J Phys Chem B; 2017 Apr; 121(15):3352-3363. PubMed ID: 27715044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation pathway of Src kinase reveals intermediate states as targets for drug design.
    Shukla D; Meng Y; Roux B; Pande VS
    Nat Commun; 2014 Mar; 5():3397. PubMed ID: 24584478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
    Hu X; Chen F
    Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular Dynamics Studies on D835N Mutation in FLT3-Its Impact on FLT3 Protein Structure.
    Swetha RG; Ramaiah S; Anbarasu A
    J Cell Biochem; 2016 Jun; 117(6):1439-45. PubMed ID: 26566084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of SRC family kinases in FLT3 signaling.
    Kazi JU; Rönnstrand L
    Int J Biochem Cell Biol; 2019 Feb; 107():32-37. PubMed ID: 30552988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.
    Kazi JU; Chougule RA; Li T; Su X; Moharram SA; Rupar K; Marhäll A; Gazi M; Sun J; Zhao H; Rönnstrand L
    Cell Mol Life Sci; 2017 Jul; 74(14):2679-2688. PubMed ID: 28271164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.
    Smith CC; Lin K; Stecula A; Sali A; Shah NP
    Leukemia; 2015 Dec; 29(12):2390-2. PubMed ID: 26108694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.
    Mitina O; Warmuth M; Krause G; Hallek M; Obermeier A
    Ann Hematol; 2007 Nov; 86(11):777-85. PubMed ID: 17668209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FMS-like tyrosine kinase 3 (FLT3) inhibitors: Molecular docking and experimental studies.
    Mashkani B; Tanipour MH; Saadatmandzadeh M; Ashman LK; Griffith R
    Eur J Pharmacol; 2016 Apr; 776():156-66. PubMed ID: 26896780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition path theory analysis of c-Src kinase activation.
    Meng Y; Shukla D; Pande VS; Roux B
    Proc Natl Acad Sci U S A; 2016 Aug; 113(33):9193-8. PubMed ID: 27482115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.
    Göring S; Bensinger D; Naumann EC; Schmidt B
    ChemMedChem; 2015 Mar; 10(3):511-22. PubMed ID: 25677073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
    Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-range molecular dynamics show that inactive forms of Protein Kinase A are more dynamic than active forms.
    Kalaivani R; Narwani TJ; de Brevern AG; Srinivasan N
    Protein Sci; 2019 Mar; 28(3):543-560. PubMed ID: 30468265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
    Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
    EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.